within Pharmacolibrary.Drugs.ATC.L;

model L01EX12
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.34,
    Cl             = 0.00029,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.048299999999999996,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015666666666666666,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.0348,
    k12             = 18.2,
    k21             = 18.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EX12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor approved for the treatment of adult and pediatric patients with solid tumors harboring an NTRK gene fusion. It is indicated for use irrespective of tumor type or site of origin, provided the tumor carries an NTRK gene fusion. Larotrectinib is approved for use in the US, EU, and other territories.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult and pediatric patients with NTRK fusion-positive tumors; parameters are derived from a two-compartment model with first-order absorption following oral administration of varied doses (including 100 mg twice daily in adults).</p><h4>References</h4><ol><li><p>Wang, Y, et al., &amp; Schinkel, AH (2022). Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 170 197–207. DOI:<a href=\"https://doi.org/10.1016/j.ejpb.2021.12.007\">10.1016/j.ejpb.2021.12.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34952136/\">https://pubmed.ncbi.nlm.nih.gov/34952136</a></p></li><li><p>Wang, Y, et al., &amp; Schinkel, AH (2020). OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. <i>British journal of pharmacology</i> 177(13) 3060–3074. DOI:<a href=\"https://doi.org/10.1111/bph.15034\">10.1111/bph.15034</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32087611/\">https://pubmed.ncbi.nlm.nih.gov/32087611</a></p></li><li><p>Bernsen, EC, et al., &amp; Diekstra, MHM (2022). Practical Recommendations for the Manipulation of Kinase Inhibitor Formulations to Age-Appropriate Dosage Forms. <i>Pharmaceutics</i> 14(12) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics14122834\">10.3390/pharmaceutics14122834</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36559327/\">https://pubmed.ncbi.nlm.nih.gov/36559327</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EX12;
